Unknown

Dataset Information

0

Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape.


ABSTRACT: Biomarkers are widely used at every stage of drug discovery and development. Utilisation of biomarkers has a potential to make drug discovery, development and approval processes more efficient. An overview of the current global regulatory landscape is presented in this article with particular emphasis on the validation and qualification of biomarkers, as well as legal framework for companion diagnostics. Furthermore, this article shows how the number of approved drugs with at least 1 biomarker used during development (biomarker acceptance) is affected by the recent advances in the biomarker regulations. More than half of analysed approvals were supported by biomarker data and there has been a slight increase in acceptance of biomarkers in recent years, even though the growth is not continuous. For certain pharmacotherapeutic groups, approvals with biomarkers are more common than without. Examples include immunosuppressants, immunostimulants, drugs used in diabetes, antithrombotic drugs, antineoplastic agents and antivirals. As a conclusion, potential benefits, challenges and opportunities of using biomarkers in drug discovery and development in the current regulatory landscape are summarised and discussed.

SUBMITTER: Gromova M 

PROVIDER: S-EPMC7727038 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape.

Gromova Mariya M   Vaggelas Annegret A   Dallmann Gabriele G   Seimetz Diane D  

Biomarker insights 20201208


Biomarkers are widely used at every stage of drug discovery and development. Utilisation of biomarkers has a potential to make drug discovery, development and approval processes more efficient. An overview of the current global regulatory landscape is presented in this article with particular emphasis on the validation and qualification of biomarkers, as well as legal framework for companion diagnostics. Furthermore, this article shows how the number of approved drugs with at least 1 biomarker u  ...[more]

Similar Datasets

| S-EPMC8682944 | biostudies-literature
| S-EPMC6966183 | biostudies-literature
| S-EPMC6768308 | biostudies-literature
| S-EPMC7933059 | biostudies-literature
| S-EPMC8261079 | biostudies-literature
| S-EPMC6209564 | biostudies-literature
| S-EPMC7748010 | biostudies-literature
| S-EPMC9732806 | biostudies-literature
| S-EPMC8458962 | biostudies-literature
| S-EPMC10100318 | biostudies-literature